慢性貧血および輸血性ヘモジデローシス患者におけるデフェラシロクスの有効性と安全性

基本情報

NCT ID

NCT00631163

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

102

治験依頼者名

Novartis

概要

The overall purpose of this trial is to further evaluate the efficacy and safety of deferasirox, dosed initially according to the transfusional iron intake, in patients with transfusion dependant anemia related to disorders other than β-thalassemia and sickle cell disease. During the study, the dose will be adjusted based on serum Ferritin.The overall purpose of the extension is to allow further treatment of patients who have already completed the core study, and to enable collection of long term efficacy and safety data. Patients will continue to receive Deferasirox at the dose they received at the end of the core study.

対象疾患

介入

依頼者（Sponsor）